Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VARUBI (ROLAPITANT HYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VARUBI
NDA
Get alerts
ROLAPITANT HYDROCHLORIDE | N206500 | TERSERA THERAPEUTICS LLC
1 strength
7 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
DMF
Approvals
Label
Products
Patent Timeline
7 unique patents by expiration date
Expiring < 1yr (4)
Active (3)
Today
2027
2028
2029
Today
7049320
Aug. 19, 2028
7563801
Apr. 4, 2027
7981905
Apr. 4, 2027
8178550
Apr. 4, 2027
8361500
Oct. 9, 2029
8404702
Apr. 4, 2027
8470842
Jan. 18, 2029
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 90MG BASE
RLD
7 patents
0 exclusivities
▴
TABLET;ORAL | Approved: Sep 1, 2015
Patents (7)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7049320
Aug 19, 2028
—
Yes
Yes
U-1741
PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
—
7563801
Apr 4, 2027
—
—
Yes
—
—
7981905
Apr 4, 2027
—
—
—
U-1741
PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
—
8178550
Apr 4, 2027
—
Yes
Yes
—
—
8361500
Oct 9, 2029
—
—
Yes
—
—
8404702
Apr 4, 2027
—
—
—
U-1741
PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
—
8470842
Jan 18, 2029
—
—
—
U-1741
PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
—